Dr. Hamid on Patient Selection for Immunotherapy Regimens in Melanoma – OncLive
OncLive |
Dr. Hamid on Patient Selection for Immunotherapy Regimens in Melanoma
OncLive Omid A. Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses how to accurately select patients who are likely to have durable and long responses with … |
